Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rhenium (186Re) obisbemeda - Plus Therapeutics

Next Previous
Drug Profile

Rhenium (186Re) obisbemeda - Plus Therapeutics

Alternative Names: 186-Rheneium nanoliposome-Plus Therapeutics; 186RNL; Re-186; REYOBIQ™; Rhenium Re186 Obisbemeda; Rhenium-186 NanoLiposome; RNL™

Latest Information Update: 16 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plus Therapeutics
  • Class Antineoplastics; Heavy metals; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Meningeal carcinomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Meningeal carcinomatosis
  • Phase II Glioblastoma
  • Phase I/II Ependymoma; Glioma
  • No development reported Peritoneal cancer; Squamous cell cancer

Most Recent Events

  • 08 Apr 2026 Rhenium (186Re) obisbemeda - Plus Therapeutics receives Orphan Drug status for Glioma (In infants, In children, In adolescents, In neonates) in USA
  • 23 Jan 2026 Plus Therapeutics anticipate REYOBIQ pivotal trial readiness
  • 23 Jan 2026 Plus Therapeutics completes enrolment in its phase IIb ReSPECT-GBM trial for Glioblastoma (Recurrent) USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top